XEJ Stoklara Genel Bakış Accuray Incorporated, Amerika Birleşik Devletleri, Kanada, Latin Amerika, Asya, Avustralya, Yeni Zelanda, Avrupa, Orta Doğu, Hindistan, Afrika, Japonya ve Çin'de tümörlerin tedavisi için radyocerrahi ve radyasyon terapi sistemleri tasarlar, geliştirir, üretir ve satar. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Accuray Incorporated Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Accuray Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$1.75 52 Haftanın En Yüksek Seviyesi US$2.66 52 Haftanın En Düşük Seviyesi US$1.27 Beta 1.46 1 Aylık Değişim -8.38% 3 Aylık Değişim 13.64% 1 Yıllık Değişim -34.21% 3 Yıllık Değişim -58.53% 5 Yıllık Değişim -28.86% Halka arzdan bu yana değişim -91.59%
Son Haberler & Güncellemeler
Accuray Incorporated Announces the Departure of Michael Hoge as Senior Vice President, Global Operations, Effective January 6, 2025 Dec 14
Accuray Incorporated Approves to Appoint Michael Murphy as the Principal Accounting Officer, Effective December 2, 2024 Nov 28
Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025 Nov 08
Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025 Nov 07
Accuray Incorporated to Report Q1, 2025 Results on Nov 06, 2024 Oct 24
Accuray Incorporated Announces CEO Changes Oct 15 Daha fazla güncelleme görün
Accuray Incorporated Announces the Departure of Michael Hoge as Senior Vice President, Global Operations, Effective January 6, 2025 Dec 14
Accuray Incorporated Approves to Appoint Michael Murphy as the Principal Accounting Officer, Effective December 2, 2024 Nov 28
Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025 Nov 08
Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025 Nov 07
Accuray Incorporated to Report Q1, 2025 Results on Nov 06, 2024 Oct 24
Accuray Incorporated Announces CEO Changes Oct 15
Accuray Incorporated, Annual General Meeting, Nov 21, 2024 Oct 07 Accuray Incorporated announced delayed annual 10-K filing Sep 17
Accuray Incorporated President Suzanne Winter to Take Temporary Medical Leave of Absence
Forecast breakeven date pushed back to 2026 Aug 16
Full year 2024 earnings released: US$0.16 loss per share (vs US$0.098 loss in FY 2023) Aug 15
Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2025 Aug 15
Accuray Incorporated to Report Q4, 2024 Results on Aug 14, 2024 Aug 01
Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products Administration Jun 15
Forecast breakeven date pushed back to 2026 Jun 06
Independent Chairman of the Board recently bought €144k worth of stock Jun 02
Accuray Incorporated Announces Executive Changes, Effective May 17, 2024 May 11
Now 21% undervalued after recent price drop May 03
Accuray Incorporated Provides Earnings Guidance for the Year 2024 May 03
Third quarter 2024 earnings released: US$0.064 loss per share (vs US$0.006 profit in 3Q 2023) May 02
Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024 Apr 26
Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024 Apr 19
Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System Mar 26
New minor risk - Share price stability Feb 14
New minor risk - Shareholder dilution Feb 08
Second quarter 2024 earnings released: US$0.098 loss per share (vs US$0.02 loss in 2Q 2023) Feb 02
Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024 Feb 01
Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024 Jan 17
President recently sold €149k worth of stock Dec 06
First quarter 2024 earnings released: US$0.031 loss per share (vs US$0.058 loss in 1Q 2023) Nov 08
President recently sold €93k worth of stock Nov 06
Accuray Incorporated to Report Q1, 2024 Results on Nov 07, 2023 Oct 27
Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration Oct 05
Accuray Incorporated, Annual General Meeting, Nov 09, 2023 Sep 30
Forecast breakeven date pushed back to 2025 Aug 11 Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024
Forecast to breakeven in 2024 Aug 10
Accuray Incorporated to Report Q4, 2023 Results on Aug 09, 2023 Jul 28
President recently sold €60k worth of stock Jul 05
Insider recently sold €87k worth of stock Jun 04
Accuray Incorporated Announces New Data Presented at the European Society for Radiotherapy and Oncology May 18
Third quarter 2023 earnings released: EPS: US$0.006 (vs US$0.011 loss in 3Q 2022) Apr 28
Accuray Incorporated Announces Data from Randomized, Multicenter Trial PACE-A Feb 17
High number of new directors Feb 07
Accuray Incorporated Reiterates Earnings Guidance for the Year 2023 Feb 04
Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.002 profit in 2Q 2022) Feb 03
Accuray Incorporated Announces the Appointment of Robert C. Kill to its Board of Directors Feb 02
Accuray Incorporated to Report Q2, 2023 Results on Feb 01, 2023 Jan 19
Accuray Incorporated Announces First Patient Treatments in New Zealand with the CyberKnife(R) System Jan 18
Accuray Incorporated Announces Intent to Resign from Position as Chief Accounting Officer and Principal Accounting Officer, Effective January 3, 2023 Dec 23
First quarter 2023 earnings released: US$0.058 loss per share (vs US$0.011 loss in 1Q 2022) Nov 05
President recently sold €77k worth of stock Nov 04
Accuray Incorporated Re-Affirms Guidance for Year 2023 Nov 03
Accuray Announces Tomo C Registration Submission to China's National Medical Products Administration Nov 02
High number of new directors Oct 31
Japanese Ministry of Health, Labor and Welfare Approves Reimbursement for the Cyberknife(R) System for the Treatment of Trigeminal Neuralgia Oct 27
Accuray Incorporated to Report Q1, 2023 Results on Nov 02, 2022 Oct 20
Accuray Incorporated Announces Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators Oct 12 Accuray Incorporated, Annual General Meeting, Nov 10, 2022
Richard R. Pettingill Not to Stand for Re-Election as Class I Director of Accuray Incorporated Sep 22
Accuray Incorporated Appoints Seth Blacksburg as Chief Medical Officer Sep 15
Full year 2022 earnings released: US$0.058 loss per share (vs US$0.069 loss in FY 2021) Aug 12
Accuray Incorporated Provides Revenue Guidance for Year 2023 Aug 11
Accuray Incorporated to Report Q4, 2022 Results on Aug 10, 2022 Jul 28
Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications Jul 13
Accuray Incorporated(NasdaqGS:ARAY) dropped from Russell 3000E Index Jun 26
Accuray Incorporated Appoints Franco N. Palomba as Chief Accounting Officer & Controller Jun 16
High number of new directors Jun 01
Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer May 18
Accuray Incorporated Announces That Clinical Studies Continue to Validate the Versatility of the Company's Cyberknife® and Tomotherapy® Platforms May 12
High number of new directors May 06
Third quarter 2022 earnings released: US$0.011 loss per share (vs US$0.004 loss in 3Q 2021) Apr 28 Accuray Incorporated Re-Affirms Earnings Guidance for the Fiscal Year 2022
Accuray Incorporated to Report Q3, 2022 Results on Apr 27, 2022 Apr 14
National Institute for Health and Care Excellence Endorses Radiosurgery Treatments for Trigeminal Neuralgia, Supporting Accuray Incorporated's CyberKnife System Indications for Use Mar 01
Accuray Incorporated Announces Data from Phase III, Randomized Controlled Trial, TomoBreast Feb 11
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Jan 28
Accuray Incorporated Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022 Jan 27
Accuray CyberKnife Robotic Radiosurgery System Receives Shonin Approval to Treat Trigeminal Neuralgia, a Chronic Pain Condition Affecting a Facial Nerve Dec 16
President recently sold €106k worth of stock Nov 10
First quarter 2022 earnings released: US$0.011 loss per share (vs US$0.004 profit in 1Q 2021) Nov 05
High number of new directors Oct 07
CEO & Director recently sold €54k worth of stock Oct 06
Accuray Incorporated Announces Nagoya City University Hospital in Aichi Treats the First Cancer Patient in Japan Using the Radixact System with Clearrt Helical Fan-Beam kVCT Imaging Sep 24
Accuray Cyberknife® Robotic Radiotherapy Platform is Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients Sep 15
Senior VP & CFO Shigeyuki Hamamatsu has left the company Sep 07
Independent Chairman of the Board recently bought €54k worth of stock Aug 22
Full year 2021 earnings released: US$0.069 loss per share (vs US$0.043 profit in FY 2020) Aug 13
Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2022 Aug 12
Accuray Expands Cyberknife® System Versatility with Integration of Raysearch's Raystation Treatment Planning System Jun 17
Accuray Incorporated Is Not Providing Earnings Guidance for Fiscal Year 2021 Apr 29 Hissedar Getirileri XEJ DE Medical Equipment DE Pazar 7D 2.9% -0.5% -0.3% 1Y -34.2% -8.4% 7.0%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: XEJ geçen yıl % -8.4 oranında getiri sağlayan German Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: XEJ geçen yıl % 7 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is XEJ's price volatile compared to industry and market? XEJ volatility XEJ Average Weekly Movement 9.2% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: XEJ hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: XEJ 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Accuray Incorporated, Amerika Birleşik Devletleri, Kanada, Latin Amerika, Asya, Avustralya, Yeni Zelanda, Avrupa, Orta Doğu, Hindistan, Afrika, Japonya ve Çin'de tümörlerin tedavisi için radyocerrahi ve radyasyon terapi sistemleri tasarlar, geliştirir, üretir ve satar. Omurga üzerindeki veya yakınındaki ve meme, böbrek, karaciğer, akciğer, pankreas ve prostattaki tümörler dahil olmak üzere beyin dışındaki primer ve metastatik tümörlerin tedavisinde kullanılan robotik bir stereotaktik radyocerrahi ve stereotaktik vücut radyasyon tedavisi sistemi olan CyberKnife platformunu sunmaktadır. Şirket ayrıca klinisyenlerin günde yaklaşık 50 hastaya ultra hassas tedaviler sunmasını sağlayan entegre radyasyon tedavisi planlama, uygulama ve veri yönetimine olanak tanıyan Radixact Sistemini içeren TomoTherapy platformunu; tam entegre bir tedavi planlama ve veri yönetim sistemi olan iDMS veri yönetim sistemini ve bir tedavi planlama ve veri yönetim sistemi olan Accuray hassas tedavi planlama sistemini sunmaktadır.
Daha fazla göster Accuray Incorporated Temel Bilgiler Özeti Accuray'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? XEJ temel i̇stati̇sti̇kler Piyasa değeri €187.45m Kazançlar(TTM ) -€15.88m Gelir(TTM ) €426.79m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) XEJ gelir tablosu (TTM ) Gelir US$444.20m Gelir Maliyeti US$306.11m Brüt Kâr US$138.10m Diğer Giderler US$154.63m Kazançlar -US$16.53m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/26 03:21 Gün Sonu Hisse Fiyatı 2024/12/23 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2024/06/30
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Accuray Incorporated 24 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Jason Wittes Aegis Capital Corporation Jason Wittes Brean Capital Neil Chatterji B. Riley Securities, Inc.
Göster 21 daha fazla analist 
